Navigation Links
Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/7/2011

BURLINGTON, Mass., Dec. 7, 2011 /PRNewswire/ -- Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that Dr. Bobby W. Sandage, Jr., the Company's President, Chief Executive Officer and Director, will present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011 at 10:30 AM ET.  The conference will be held at The Waldorf-Astoria Hotel in New York City on December 13-14, 2011.

A webcast of this presentation will be available at www.coronadobiosciences.com on the events page. 

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.  For more information, please visit www.coronadobiosciences.com

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact Information:

Investor Relations

Noah D. Beerman, Executive Vice President & Chief Operating Officer
Coronado Biosciences, Inc.
781-238-6619; ir@coronadobio.com

Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Media Relations

Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159; dobsonpr@erols.com


'/>"/>
SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2020)... FARMINGTON, Conn. (PRWEB) , ... February 04, 2020 ... ... that develops tools for characterizing microbiome populations down to the strain level, has ... Limited, will sell Shoreline Biome’s microbiome kits and other products to companies and ...
(Date:1/28/2020)... FORT WORTH, Texas (PRWEB) , ... January 28, ... ... Midland Scientific to be the exclusive distributor to food and beverage manufactures ... years and are considered critical suppliers. This agreement will allow each company to ...
(Date:1/27/2020)... ... January 27, 2020 , ... ... secured financing from strategic investors led by Halma plc , a FTSE ... Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant CEO and ... at two recent North American investor forums specializing in medical advancements. New technology ... & Diagnostics Forum on November 21, 2019 in New York City, and the ...
Breaking Biology Technology:
(Date:1/23/2020)... ... January 23, 2020 , ... Asymmetrex LLC ... Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th ... organizations from industry, government, academia and the non-profit sector to develop next-generation ...
(Date:1/22/2020)... ... 2020 , ... Lifecycle Biotechnologies announces the new line of high purity powder chemicals ... on their process requirements and accurately weighed to 0.001 of a gram. The new line ... Sugars , Carbohydrates , Phosphates , Chelators ...
(Date:1/10/2020)... (PRWEB) , ... January 09, 2020 , ... ... of bioactive spinal solutions, today announced the 510(K) clearance and commercial launch of ... lateral interbody fusion system. , The EVOL®ha-DLIF is made of PEEK-OPTIMA HA ...
Breaking Biology News(10 mins):